Express Mail Label No.: EV942367501US

Date of Deposit: June 29, 2007

AMENDMENT

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently Amended) A method of treating leukemia in a subject, said method comprising the step of orally administering to the subject a total daily dose of up to 800 400 mg once daily of a pharmaceutical composition comprising suberoylanilide hydroxamic acid (SAHA) represented by the structure:

or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier or diluent, wherein administration of SAHA or a pharmaceutically acceptable salt or hydrate thereof is effective to treat leukemia in said subject.

- 2. (Original) The method of claim 1, wherein the leukemia is an acute leukemia.
- 3. (Original) The method of claim 2, wherein the leukemia is Acute Myeloid Leukemia (AML).
 - 4-11. (Cancelled)
- 12. (Previously Presented) The method of claim 1, wherein said composition is contained within a gelatin capsule.
- 13. (Original) The method of claim 12, wherein said carrier or diluent is microcrystalline cellulose.

Attorney Docket No. 24852-513

Express Mail Label No.: EV942367501US

Date of Deposit: June 29, 2007

14. (Currently Amended) The method of claim 13 1, said composition further comprising sodium croscarmellose as a disintegrating agent.

15. (Currently Amended) The method of claim 14 1, said composition further comprising magnesium stearate as a lubricant.

16-156. (Cancelled)

157. (Currently Amended) The method of any one of claims 1, 2, 3 and 12-15 95 95, 97, 99, 101-103, 105, 107, 109 111, 113, 115, 117-119, 121, 123, 125-127, 129, 131, 133-135, 137, 139 or 141-142, wherein SAHA is the active ingredient in said composition.

158.-178. (Cancelled)